{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:32:44Z","timestamp":1767864764092,"version":"3.49.0"},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Erenumab is a human anti\u2010calcitonin gene\u2010related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess the temporal patterns of response to erenumab in patients with chronic migraine (CM), specifically the onset and sustainability of monthly migraine day (MMD) response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a post hoc analysis of a 12\u2010week, randomized, double\u2010blind, placebo\u2010controlled study of erenumab for migraine prevention in patients with CM (\u226515\u00a0headache days\/month, including \u22658\u00a0migraine days\/month). Onset and sustainability were assessed according to MMD reduction from baseline, with the following response categories: responders (\u226550% reduction), partial responders (\u226530% and &lt;50%), or nonresponders (&lt;30%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the erenumab 140\u00a0mg group (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0187), 54.0% (101\/187) achieved a response at any month during the study with a median time to onset of monthly response of 1\u00a0month. This improvement was maintained in most patients with continued treatment. An initial response was achieved at Month 1 by 28.3% (53\/187) of patients; 69.8% (37\/53) of whom maintained a response at Months 2 and 3. Although many patients responded early, some patients required longer treatment to achieve a response; 79.4% (27\/34) of initial partial responders and 21.0% (21\/100) of initial nonresponders subsequently achieved a response. Similar findings were observed for the erenumab 70mg group (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0188).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A majority of erenumab\u2010treated patients with CM who achieved an initial response at Month 1 sustained this benefit. Many patients responded later with continued treatment. Our data support recommendations to assess outcomes after \u22653\u00a0months of preventive treatment with erenumab in CM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14193","type":"journal-article","created":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T12:51:42Z","timestamp":1628340702000},"page":"1255-1263","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Timing and durability of response to erenumab in patients with chronic migraine"],"prefix":"10.1111","volume":"61","author":[{"given":"Stewart J.","family":"Tepper","sequence":"first","affiliation":[{"name":"Geisel School of Medicine at Dartmouth Hanover NH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Lucas","sequence":"additional","affiliation":[{"name":"University of Washington Medical Center Seattle WA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6218-4744","authenticated-orcid":false,"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[{"name":"Danish Headache Center University of Copenhagen Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd J.","family":"Schwedt","sequence":"additional","affiliation":[{"name":"Mayo Clinic Phoenix AZ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[{"name":"Medstar Georgetown University Washington DC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Scanlon","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Klatt","sequence":"additional","affiliation":[{"name":"Novartis Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise E.","family":"Chou","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Wang","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Paiva da Silva Lima","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8,7]]},"reference":[{"key":"e_1_2_12_2_1","volume-title":"Aimovig (erenumab\u2010aooe)","year":"2020"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12618"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418758283"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007497"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0787-1"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13443"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418821662"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0923-6"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0955-y"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004391"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14715"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471\u20104159.2006.04161.x"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-307149"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414527648"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2183-6"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000581"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:31:00Z","timestamp":1762090260000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,7]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/head.14193"],"URL":"https:\/\/doi.org\/10.1111\/head.14193","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,7]]},"assertion":[{"value":"2021-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}